Sunobinop

Sunobinop
Clinical data
Other names	IMB-115
Drug class	Nociceptin receptor agonist
Identifiers
	IUPAC name 4-[(1R,5S)-9-[(1S,5S)-3-bicyclo[3.3.1]nonanyl]-9-azabicyclo[3.3.1]nonan-3-yl]-3-oxoquinoxaline-2-carboxylic acid;
CAS Number	1126793-40-5;
PubChem CID	155801560;
ChemSpider	34950269;
UNII	I1X86U5474;
ChEMBL	ChEMBL4650344;
Chemical and physical data
Formula	C26H33N3O3
Molar mass	435.568 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(O)C1=NC=2C=CC=CC2N(C1=O)C3CC4N(C(CCC4)C3)C5CC6CCCC(C5)C6;
	InChI InChI=1S/C26H33N3O3/c30-25-24(26(31)32)27-22-9-1-2-10-23(22)29(25)21-14-18-7-4-8-19(15-21)28(18)20-12-16-5-3-6-17(11-16)13-20/h1-2,9-10,16-21H,3-8,11-15H2,(H,31,32)/t16-,17-,18-,19+,21?/m0/s1; Key:COTYYZPYDJKKIS-MCXOOUIESA-N;

Sunobinop (developmental code names V117957; IMB-115) is a high affinity small molecule nociceptin receptor partial agonist.^[1]

As of February 2024, it is under clinical investigation for the treatment of insomnia/alcohol use disorder, interstitial cystitis, and overactive bladder syndrome.^[2]^[3] It was previously also under investigation for the treatment of fibromyalgia.^[1]

^ ^a ^b "Sunobinop - Shionogi/Imbrium Therapeutics". AdisInsight. Springer Nature Switzerland AG.
^ "Pipeline". Imbrium Therapeutics. Retrieved May 1, 2024.
^ WO application 2018020418, Harris SC, Kapil RP, Kyle DJ, Whiteside G, "Treatment and prevention of sleep disorders", published 2018-02-01, assigned to Purdue Pharma L.P.